Mesenteric Ischaemia

1. Clinical Overview

Summary

Mesenteric ischaemia is a life-threatening condition characterized by inadequate blood supply to the intestines, leading to bowel infarction and potentially fatal complications. It occurs in acute and chronic forms, with acute mesenteric ischaemia (AMI) being a surgical emergency with mortality rates of 60-80%, varying by etiology and time to diagnosis. The condition requires high clinical suspicion, prompt diagnosis, and urgent intervention combining medical resuscitation, anticoagulation, and surgical or endovascular management. Chronic mesenteric ischaemia (CMI) presents as postprandial abdominal pain ("intestinal angina") and weight loss, requiring elective revascularization. Early recognition is crucial as delays in diagnosis significantly worsen outcomes, with mortality exceeding 90% when diagnosis is delayed beyond 48 hours. The four main subtypes of AMI—arterial embolism (40-50%), arterial thrombosis (25-30%), venous thrombosis (5-15%), and non-occlusive mesenteric ischaemia (NOMI, 20-25%)—each require distinct management approaches. [1,2,21]

Key Facts

• Incidence: Acute: 0.1-0.2% of acute surgical admissions; Chronic: Rare (less than 1 per 100,000).
• Mortality: Acute: 30-90% (highest of abdominal emergencies); Chronic: less than 5% with treatment.
• Age Distribution: Peak incidence 60-80 years; rare in young adults.
• Male:Female Ratio: 1:1 in acute forms; 1:3 in chronic forms.
• Hospital Stay: Survivors require 2-4 weeks ICU care on average.
• Long-term Sequelae: 20-30% develop short bowel syndrome requiring TPN.

Clinical Pearls

The Silent Killer: Mesenteric ischaemia is often called the "silent killer" because early symptoms are subtle and examination findings minimal until bowel infarction occurs.

Pain Out of Proportion: Severe abdominal pain with minimal tenderness is the classic presentation - suspect mesenteric ischaemia until proven otherwise.

The Window of Opportunity: Viable bowel can be salvaged up to 6-12 hours after onset; beyond this, resection is inevitable.

Triple Threat: Most cases involve occlusion of the superior mesenteric artery (SMA), the vessel supplying 90% of small bowel blood flow.

Embolus vs. Thrombosis Pearl: [21,29]

• Embolus: Sudden pain, atrial fibrillation history, normal bowel function yesterday, occlusion 3-10cm from SMA origin
• Thrombosis: Recent post-prandial pain (chronic disease), heavy atherosclerotic burden, occlusion at SMA origin, extensive collaterals

Lactate Paradox: Normal lactate does NOT exclude early AMI—it rises only after bowel necrosis begins. In the first 6 hours, 40% of AMI patients have normal lactate. [25]

Second-Look Decision: If uncertain about bowel viability after revascularization, always plan second-look at 24-48 hours. The risk of anastomotic leak from ischemic bowel is 5-10 times higher than for healthy bowel. [31]

Why This Matters Clinically

• Surgical Emergency: Highest mortality of any abdominal emergency when missed.
• Diagnostic Challenge: Non-specific early symptoms, normal early examinations.
• Multidisciplinary Care: Requires vascular surgeons, intensivists, gastroenterologists.
• Preventable: Smoking cessation, anticoagulation, and cardiac source treatment reduce risk.
• Resource Intensive: Survivors often require prolonged ICU stay and nutritional support.
• Quality Indicator: Time to diagnosis and intervention affects hospital quality metrics.

Acute vs. Chronic Mesenteric Ischaemia: Critical Differentiation

Clinical Challenge: Differentiating acute from chronic forms is essential as management and prognosis differ dramatically. [22]

• sitophobia) | | Examination | Initially benign, then peritonitic | Usually soft abdomen, abdominal bruit (50%) | | Lactate | Elevated (> 2 mmol/L in 90%) | Normal | | Bloody Diarrhea | Late sign (mucosal necrosis) | Rare | | CT Findings | Vessel occlusion, bowel wall changes, pneumatosis | Atherosclerotic stenosis of ≥2 vessels | | Mortality | 60-80% | less than 5% with treatment | | Treatment | Emergency laparotomy or endovascular | Elective revascularization | | Timeframe | Hours matter (6-12 hour window) | Weeks to months (plan intervention) |

Acute-on-Chronic: 10-15% of AMI cases occur in patients with pre-existing chronic disease—sudden thrombosis superimposed on chronic stenosis. These patients may report weeks of post-prandial pain before the acute event. [23]

---

2. Epidemiology

Global Burden

• Annual Incidence: Acute: 1-2 per 100,000 population; Chronic: 0.05-0.1 per 100,000.
• Hospital Admissions: 0.1-0.2% of acute surgical admissions present with acute mesenteric ischaemia.
• Age-Specific Rates: less than 50 years: 0.02 per 100,000; 50-70 years: 0.5 per 100,000; > 70 years: 2-3 per 100,000.
• Geographic Variation: Higher in developed countries with aging populations.
• Economic Impact: $1-2 billion annually in US healthcare costs.

Risk Factors and Odds Ratios

Aetiological Distribution

Acute Mesenteric Ischaemia (AMI):

• Arterial Embolism: 40-50% - SMA occlusion from cardiac sources.
• Arterial Thrombosis: 20-30% - Atherosclerotic plaque rupture.
• Venous Thrombosis: 5-15% - Mesenteric vein thrombosis.
• Non-Occlusive: 20-25% - Low flow states in shock/critical illness.

Chronic Mesenteric Ischaemia (CMI):

• Atherosclerosis: 80-90% - Stenosis of ≥2 mesenteric vessels.
• Vasculitis: 5-10% - Takayasu's, PAN, SLE.
• Fibromuscular Dysplasia: 2-5% - Young women.
• Median Arcuate Ligament Syndrome: 2-3% - Celiac compression.

Outcomes and Mortality

• Overall Mortality: AMI: 60-80%; CMI: less than 5% with treatment.
• Early Diagnosis: Mortality 30-50% if diagnosed within 24 hours.
• Late Diagnosis: Mortality > 90% if diagnosed after 48 hours.
• Bowel Resection: Required in 70-80% of AMI cases.
• Short Bowel Syndrome: Occurs in 20-30% of survivors.

---

3. Pathophysiology

Step 1: Vascular Occlusion or Hypoperfusion

• Arterial Embolism: Cardiac thrombus (AF, post-MI) embolizes to SMA.
• Arterial Thrombosis: Atherosclerotic plaque rupture with thrombosis.
• Venous Thrombosis: Mesenteric vein thrombosis from hypercoagulable states.
• Hypoperfusion: Shock states reduce splanchnic blood flow.

Step 2: Ischaemic Cascade Initiation

• Oxygen Deprivation: Mucosal cells most susceptible (anaerobic metabolism).
• ATP Depletion: Cellular energy failure within minutes.
• Ion Pump Failure: Sodium-potassium pump dysfunction.
• Cellular Swelling: Intracellular edema, mucosal barrier breakdown.

Step 3: Mucosal and Submucosal Injury

• Increased Permeability: Loss of tight junctions, bacterial translocation.
• Inflammatory Response: Cytokine release (TNF-α, IL-6), neutrophil infiltration.
• Acid-Base Imbalance: Lactic acid production, metabolic acidosis.
• Vasodilation: Compensatory response attempting to improve flow.

Step 4: Transmural Necrosis

• Full-Thickness Injury: All bowel layers affected.
• Bacterial Invasion: Gut flora enter bloodstream and peritoneal cavity.
• Peritonitis: Chemical and bacterial peritonitis.
• Sepsis: Systemic inflammatory response, multiorgan dysfunction.

Step 5: Systemic Complications

• Cardiovascular Collapse: Septic shock, cardiac depression.
• Acute Respiratory Distress: Pulmonary edema, ARDS.
• Acute Kidney Injury: ATN from hypoperfusion and sepsis.
• Disseminated Intravascular Coagulation: Consumption coagulopathy.

Pathophysiological Variants

Arterial Embolism:

• Sudden onset, watershed distribution.
• Jejunum spared (arcades), ileum/colon affected.

Arterial Thrombosis:

• Progressive atherosclerosis, acute thrombosis.
• Extensive small bowel involvement.

Venous Thrombosis:

• Gradual onset, entire bowel wall affected.
• More edema, less hemorrhage.

Non-Occlusive Mesenteric Ischaemia (NOMI):

• Diffuse vasoconstriction in critically ill.
• Multiple small infarcts, patchy involvement.

---

4. Clinical Presentation

Acute Mesenteric Ischaemia

Classic Triad:

• Severe Abdominal Pain: "Pain out of proportion"
• sudden, severe, constant.
• Diarrhea: Often bloody, "empty rectum" on PR examination.
• Cardiac Source: History of AF, recent MI, or cardiac symptoms.

Symptoms by Frequency

Signs and Examination Findings

Early Phase (0-6 hours):

• Minimal tenderness, normal bowel sounds.
• Mild tachycardia, normal blood pressure.
• No peritoneal signs.

Intermediate Phase (6-12 hours):

• Increasing tenderness, guarding.
• Distended abdomen, absent bowel sounds.
• Tachycardia, oliguria, mild hypotension.

Late Phase (> 12 hours):

• Severe tenderness, rebound, guarding.
• Marked distension, tympanic abdomen.
• Hypotension, tachycardia, septic appearance.
• Peritoneal signs, fever.

Chronic Mesenteric Ischaemia

"Intestinal Angina":

• Postprandial abdominal pain (15-60 minutes after eating).
• Weight loss (fear of eating).
• Borborygmi, diarrhea.
• Abdominal bruit (50% of cases).

Progressive Symptoms:

• Episodic pain → constant pain.
• Weight loss → malnutrition.
• Bowel infarction → acute abdomen.

Red Flags for Severe Disease

1. Pain Out of Proportion: Severe pain with minimal examination findings.
2. Metabolic Acidosis: Elevated lactate (> 2 mmol/L).
3. Hemodynamic Instability: Hypotension, tachycardia.
4. Peritoneal Signs: Rebound tenderness, guarding.
5. Pneumatosis Intestinalis: Gas in bowel wall on imaging.
6. Portal Venous Gas: Air in portal vein system.

---

5. Clinical Examination

Abdominal Assessment

• Inspection: Distension may be absent early, present later.
• Palpation: Initially minimal tenderness, later severe with guarding.
• Percussion: Tympany from ileus, shifting dullness if ascites.
• Auscultation: Initially hyperactive, later absent bowel sounds.

Cardiovascular Examination

• Heart Rate: Tachycardia (compensatory).
• Blood Pressure: Initially normal, later hypotension.
• JVP: Normal unless cardiac involvement.
• Peripheral Pulses: Check for atrial fibrillation, femoral pulses.

Systemic Assessment

• Mental Status: Confusion from acidosis, sepsis.
• Respiratory: Tachypnea, signs of pulmonary edema.
• Skin: Cool, clammy; petechiae if DIC.
• Extremities: Peripheral edema if hypoproteinemic.

Digital Rectal Examination

• Empty Rectum: Characteristic finding.
• Blood: Occult or gross blood.
• Tenderness: Anterior peritoneal irritation.

Monitoring Parameters

• Vital Signs: Hourly monitoring.
• Urine Output: Catheterize for accurate measurement.
• Abdominal Girth: Serial measurements.
• Pain Score: Despite pain, examination may be benign.

---

6. Investigations

Essential Investigations

1. Blood Tests

• FBC: Leukocytosis, left shift, thrombocytopenia.
• U&E: AKI, metabolic acidosis.
• Lactate: > 2 mmol/L suggests bowel ischaemia.
• Coagulation: Prolonged APTT/PT in DIC.
• CRP/Amylase: Elevated in inflammation/pancreatitis.

2. Arterial Blood Gas and Lactate

Lactate Measurement:

• Sensitivity: 86-90% for AMI when > 2 mmol/L [24,36]
• Specificity: Only 44-54% (elevated in many acute conditions) [24,36]
• Positive Predictive Value: 40-60% (many false positives) [36]
• Negative Predictive Value: 85-92% (normal lactate helpful to exclude AMI) [24]

CRITICAL LIMITATIONS OF LACTATE: [25]

1. Late Marker: Lactate rises only after substantial bowel necrosis (transmural ischemia)
2. Timing Problem: Often normal in first 6-12 hours (early reversible ischemia)
3. Non-Specific: Elevated in sepsis, shock, liver failure, diabetic ketoacidosis, seizures
4. Venous Thrombosis: May be normal in mesenteric venous thrombosis (gradual onset)
5. NOMI: Can be normal despite significant ischemia (patchy involvement)

Clinical Application:

• Normal lactate (less than 2 mmol/L): Does NOT exclude early AMI—proceed to imaging if high suspicion
• Elevated lactate (> 2 mmol/L): Supports diagnosis but requires imaging confirmation
• Lactate > 4 mmol/L: Suggests advanced ischemia with necrosis—urgent surgical consultation
• Rising lactate: Serial measurements detect progression—indicates worsening

Acidosis Parameters:

• Metabolic Acidosis: High anion gap (> 16 mEq/L)
• Base Deficit: > 6 mEq/L suggests severe disease, > 10 mEq/L indicates bowel necrosis
• pH: less than 7.30 associated with mortality > 70%

3. ECG

• Atrial Fibrillation: Source of emboli.
• Ischaemic Changes: Recent myocardial infarction.
• Arrhythmias: Contributing to low cardiac output.

Imaging Investigations

1. CT Angiography (CTA) - Gold Standard Imaging [26,27]

Diagnostic Accuracy:

• Sensitivity: 92-96% for arterial occlusion, 89-94% for bowel ischemia [26,27,35]
• Specificity: 95-100% for arterial occlusion, 85-92% for bowel necrosis [26,35]
• Positive Predictive Value: 93-97% (excellent) [35]
• Negative Predictive Value: 94-98% (excellent—normal CTA essentially excludes AMI) [27,35]
• Overall Accuracy: 94-96% [26,27]

CTA Protocol Requirements:

• Biphasic/Triphasic: Arterial phase (35-40s delay) + portal venous phase (65-70s delay)
• IV Contrast: Essential 100-150 mL @ 3-5 mL/s (contraindicated if contrast allergy/severe AKI)
• Slice Thickness: ≤1.25 mm (multidetector CT)
• Timing: Can be performed urgently (15-20 minutes)

Vascular Findings (Primary):

• SMA Occlusion: Abrupt cutoff or filling defect (embolus vs thrombosis differentiation)
  • "Embolus: Occlusion 3-10 cm from SMA origin, normal proximal vessel, cardiac source"
  • "Thrombosis: Occlusion at SMA origin, atherosclerotic calcification, collaterals present"
• Celiac/IMA Stenosis: Chronic disease (≥70% stenosis in ≥2 vessels)
• Mesenteric Vein Thrombosis: Filling defect in SMV/portal vein, bowel wall thickening

Bowel Findings (Secondary):

• Bowel Wall Thickening: > 3 mm (edema from ischemia)
• Bowel Wall Enhancement:
  • "Increased: Early ischemia (hyperemia)"
  • "Decreased/Absent: Late ischemia (necrosis)"
  • "Target Sign: Alternating layers (specific for ischemia)"
• Pneumatosis Intestinalis: Gas in bowel wall (transmural necrosis—surgical emergency)
• Portal Venous Gas: Air in portal vein branches (advanced necrosis, mortality > 75%)
• Mesenteric Stranding: Fat stranding around vessels (inflammation)
• Ascites: Free fluid (peritonitis if bowel perforation)

Limitations of CTA: [28]

1. Radiation: 10-20 mSv (avoid in pregnancy if possible)
2. Contrast Nephropathy: Risk in AKI/CKD (benefits usually outweigh risks in AMI)
3. NOMI: Vessels may appear patent—diagnosis based on bowel findings
4. Early Ischemia: Bowel may appear normal in first 6 hours
5. False Positives: Bowel wall thickening can occur in other conditions (IBD, infection)

2. Duplex Ultrasound

• SMA Velocity: Peak systolic velocity > 275 cm/s suggests stenosis.
• Limitation: Operator-dependent, bowel gas interference.
• Use: Chronic mesenteric ischaemia diagnosis.

3. Mesenteric Angiography

• Gold Standard: For diagnosis and intervention.
• Therapeutic: Allows angioplasty, stenting, thrombolysis.
• Risk: Contrast nephropathy, access complications.

Diagnostic Algorithm

SUSPECTED MESENTERIC ISCHAEMIA
         ↓
┌─────────────────────────────────────────┐
│        INITIAL ASSESSMENT              │
│  - History: pain pattern, risk factors │
│  - Examination: tenderness, vital signs│
│  - Bloods: lactate, ABG, coagulation   │
│  - ECG: atrial fibrillation?           │
└─────────────────────────────────────────┘
         ↓
    ┌─────────┴─────────┐
    ACUTE                CHRONIC
    ↓                     ↓
URGENT CTA Abdomen     CT/MR Angiogram
(within 1 hour)         ↓
    ↓                 Duplex Ultrasound
┌─────┴─────┐          ┌─────┴─────┐
POSITIVE   NEGATIVE    STENOSIS    NORMAL
   ↓           ↓        ≥2 vessels    ↓
CLASSIFY    REASSESS      ↓         EXCLUDE CMI
SUBTYPE     (Other Dx)  ANGIOGRAM  Consider other
   ↓                       ↓         diagnoses
┌──┴──┬──────┬─────┐   Intervention
EMBOLUS THROMBOSIS VENOUS NOMI  ↓
   ↓       ↓       ↓      ↓    Stent/Angio
   └───────┴───────┴──────┘      ↓
           ↓               Clinical Response?
     HEMODYNAMICALLY            ↓
       STABLE?            ┌─────┴─────┐
     ┌─────┴─────┐      YES          NO
    YES          NO      ↓            ↓
     ↓            ↓    Continue     Reassess
ENDOVASCULAR  LAPAROTOMY  Rx       (Surgery)
  Consider      ↓
     ↓      ┌───┴───┐
LAPAROTOMY  VIABLE  UNCERTAIN
if fails      ↓         ↓
     ↓      Close   SECOND-LOOK
     └────────┘    in 24-48h
         ↓
    MONITOR RECOVERY

Critical Decision Points:

1. CTA Timing: Must be performed urgently (less than 1 hour) if AMI suspected—delays increase mortality
2. Lactate Interpretation: Normal lactate + high suspicion → still do CTA (40% of early AMI have normal lactate)
3. Hemodynamic Status: Unstable patients go directly to OR (damage control); stable patients may have endovascular option
4. Second-Look Planning: Decided at initial operation—always plan if ANY uncertainty about viability

---

7. Management

Management Algorithm

MESENTERIC ISCHAEMIA DIAGNOSED
        ↓
┌─────────────────────────────────────────┐
│        IMMEDIATE RESUSCITATION         │
│  - ABCDE approach                      │
│  - IV fluids, vasopressors if shocked │
│  - Broad-spectrum antibiotics         │
│  - Analgesia, antiemetics             │
└─────────────────────────────────────────┘
        ↓
┌─────────────────────────────────────────┐
│        ANTI-COAGULATION                │
│  - Heparin infusion (unfractionated)   │
│  - Target APTT 1.5-2.5x normal        │
│  - Continue until definitive Rx       │
└─────────────────────────────────────────┘
        ↓
   ┌─────────┴─────────┐
   ACUTE (UNSTABLE)    CHRONIC (STABLE)
   ↓                   ↓
URGENT LAPAROTOMY     ELECTIVE REVASC
   ↓                   ↓
┌─────┴─────┐         Angioplasty/Stent
VIABLE     NON-VIABLE
BOWEL       BOWEL
   ↓           ↓
SECOND LOOK   RESECTION
SURGERY      + REVASC
   ↓           ↓
   ┌───────────┴───────────┐
   RECOVERY & MONITORING

Acute Mesenteric Ischaemia

Medical Management:

• Fluid Resuscitation: 1-2L crystalloid bolus, then maintenance.
• Antibiotics: Piperacillin-tazobactam + metronidazole + gentamicin.
• Anticoagulation: Heparin 5000 IU IV bolus, then 1000 IU/hour infusion.
• Analgesia: Opioids titrated to pain, avoid masking peritoneal signs.
• Anti-emetics: Ondansetron for nausea.

Surgical Management: Embolus vs. Thrombosis Differentiation [29,30]

Arterial Embolism (40-50% of AMI):

Characteristics:

• Source: Left atrium/ventricle (AF 70%, recent MI 20%, valve disease 10%)
• Location: 3-10 cm distal to SMA origin (vessel bifurcation)
• CTA Appearance: Abrupt cutoff, normal proximal SMA, minimal collaterals
• Clinical: Sudden onset, often no prior bowel symptoms

Surgical Approach:

1. Midline Laparotomy: Assess bowel (skip areas may be viable)
2. SMA Exposure: Open lesser sac, identify SMA at transverse colon base
3. Embolectomy:
   • Arteriotomy 1-2 cm distal to occlusion
   • Fogarty catheter (3-4 Fr) passed distally and proximally
   • Confirm backbleeding and forward flow
   • Close with 5-0 or 6-0 Prolene patch
4. Intraoperative Heparin: 5000 IU IV after embolectomy (prevent re-thrombosis)
5. Bowel Assessment: Wait 15-20 min post-revascularization
6. Resection: Only clearly necrotic bowel (black, no Doppler signal, no fluorescence)
7. Second-Look: Mandatory in 24-48h if viability uncertain

Prognosis Post-Embolectomy:

• Early (less than 6h): 50-60% survival
• Late (> 12h): 20-30% survival
• Bowel Resection: 70-80% require some resection

---

Arterial Thrombosis (25-30% of AMI):

Characteristics:

• Pathophysiology: Acute thrombosis on chronic atherosclerotic plaque
• Location: SMA origin (ostial stenosis)
• CTA Appearance: Occluded at origin, heavy calcification, collateral vessels
• Clinical: May have preceding CMI symptoms (weeks of post-prandial pain)

Surgical Approach:

1. Midline Laparotomy: More extensive bowel involvement than embolism
2. Revascularization Options:
   • Open Bypass: Supraceliac aorta-to-SMA bypass (6-8mm PTFE/vein graft)
     • Retrograde bypass (C-loop from infrarenal aorta)
     • Antegrade bypass (supraceliac aorta via lesser sac)
   • Endarterectomy: Transaortic if ostial lesion accessible
   • Endovascular (if stable): Angioplasty + stenting
3. Bowel Resection: Extensive (often > 50 cm), high short bowel risk
4. Second-Look: Mandatory (assess graft patency and bowel viability)

Prognosis Post-Bypass:

• 30-Day Mortality: 40-60% (worse than embolism)
• Graft Patency: 80-90% at 1 year
• Short Bowel Syndrome: 30-40% of survivors

---

Second-Look Laparotomy: Evidence-Based Protocol [31,32]

Indications for Planned Second-Look: [33]

1. Uncertain Bowel Viability: Dusky bowel that may recover post-revascularization
2. Extensive Resection Avoided: To minimize short bowel syndrome
3. Questionable Perfusion: Despite revascularization
4. Massive Bowel Edema: Precludes primary anastomosis
5. Hemodynamic Instability: Damage control—abort initial operation

Timing:

• Optimal: 24-48 hours post-initial laparotomy
• Earlier (12-24h): If clinical deterioration (rising lactate, peritonitis)
• Delayed (> 48h): If improving—may avoid second operation

Technique:

1. Temporary Abdominal Closure: VAC dressing or Bogota bag at initial operation
2. Re-Exploration: Systematic bowel assessment from ligament of Treitz to ileocecal valve
3. Viability Criteria:
   • Viable: Pink, peristalsis, Doppler arterial signal, ICG fluorescence
   • Non-Viable: Black/green, no peristalsis, no Doppler signal, no fluorescence
   • Uncertain: Purple/dusky—resect (cannot risk perforation)
4. Resection: Additional non-viable segments (mark resection sites at initial operation)
5. Anastomosis: If abdomen clean and patient stable; otherwise delayed primary anastomosis

Adjuncts to Viability Assessment: [34]

• Doppler Ultrasound: Arterial signal = viable (85% accuracy)
• Fluorescence Imaging: IV indocyanine green (90-95% accuracy)
• Wood's Lamp: Fluorescein + UV light (80% accuracy, less common now)
• Clinical Judgment: Color, peristalsis, bleeding from cut edge (70-80% accuracy)

Outcomes of Second-Look:

• Additional Resection: 30-50% require further bowel resection
• Mortality Reduction: 15-20% relative reduction vs. no second-look
• Short Bowel Syndrome: 20-35% (unavoidable in extensive disease)
• Anastomotic Leak: 5-10% (higher than elective surgery)

When Second-Look NOT Needed:

1. Clearly Viable Bowel: Normal appearance, excellent perfusion after revascularization
2. Limited Resection: less than 20 cm bowel removed, residual bowel clearly viable
3. Non-Operative Management: Endovascular only, no laparotomy
4. Palliative Care: Patient too frail for re-operation

---

Decision Algorithm: Initial Operation

ACUTE MESENTERIC ISCHAEMIA CONFIRMED
         ↓
┌────────────────────────────────────┐
│    Patient Hemodynamically Stable? │
└────────────────────────────────────┘
         ↓
    ┌────┴────┐
   YES        NO
    ↓          ↓
CONSIDER    DAMAGE CONTROL
ENDOVASCULAR   LAPAROTOMY
    ↓          ↓
CTA shows    - Rapid bowel assessment
occlusion    - Resect clearly dead bowel
at SMA       - Temporary closure (VAC)
origin?      - ICU resuscitation
    ↓          ↓
┌────┴────┐  SECOND-LOOK in 24-48h
EMBOLUS   THROMBOSIS
   ↓           ↓
Embolectomy   Open Bypass
   ↓           ↓
Bowel         Bowel
Assessment    Assessment
   ↓           ↓
┌──┴──┐    ┌──┴──┐
VIABLE  QUESTIONABLE
   ↓           ↓
Close      SECOND-LOOK
Abdomen    in 24-48h

Endovascular Options:

• Angioplasty: Balloon dilation of stenotic lesions.
• Stenting: Self-expanding stents for chronic lesions.
• Thrombolysis: Intra-arterial TPA for acute thrombosis.
• Embolectomy: Percutaneous mechanical thrombectomy.

Chronic Mesenteric Ischaemia

Medical Management:

• Risk Factor Modification: Smoking cessation, lipid control.
• Antiplatelets: Aspirin 75mg daily.
• Statins: Atorvastatin 40mg daily.
• Anticoagulation: If thrombophilic state.

Surgical Management:

• Bypass Grafting: Aorto-mesenteric bypass (SMA, celiac).
• Endarterectomy: Transaortic endarterectomy.
• Reimplantation: SMA reimplantation into aorta.

Endovascular Management:

• Angioplasty ± Stenting: Primary treatment for chronic disease.
• Retrograde Access: Brachial or axillary approach.
• Hybrid Procedures: Laparoscopic-assisted angioplasty.

Special Considerations

Nomogram Use:

• Viability Assessment: Pulse, color, peristalsis, bleeding from cut edge.
• Doppler Ultrasound: Arterial and venous signals.
• Fluorescence Imaging: Indocyanine green for perfusion assessment.

Postoperative Care:

• ICU Admission: All patients require intensive monitoring.
• Nutrition: TPN if short bowel, enteral when bowel recovers.
• Antibiotics: Continue 7-14 days, de-escalate based on cultures.
• Anticoagulation: LMWH bridging to warfarin.

Short Bowel Syndrome Management:

• Parenteral Nutrition: Central venous access, specialized team.
• Fluid/Electrolyte: Daily monitoring, supplementation.
• Vitamin/Mineral: Replacement therapy.
• Intestinal Adaptation: Teduglutide, growth hormone.

---

8. Complications

Intraoperative Complications

Systemic Complications

Long-Term Complications

---

9. Prognosis & Outcomes

Mortality Rates

• Acute Mesenteric Ischaemia: 30-90% overall mortality.
• Early Diagnosis (less than 24h): 30-50% mortality.
• Late Diagnosis (> 48h): > 90% mortality.
• Chronic Mesenteric Ischaemia: less than 5% mortality with treatment.
• Short Bowel Syndrome: 20-30% of survivors.

Prognostic Factors

Poor Prognosis:

• Age > 70 years
• Delay in diagnosis > 24 hours
• Extensive bowel resection (> 1m small bowel)
• Preoperative shock
• Multiorgan dysfunction
• Advanced age
• Comorbidities (cardiac, renal disease)

Good Prognosis:

• Early diagnosis and intervention
• Limited bowel involvement
• No preoperative shock
• Young age
• Single vessel occlusion
• Prompt revascularization

Survival Statistics

Quality of Life Outcomes

• Functional Status: 60-70% return to independent living.
• Nutritional Status: 70% require ongoing nutritional support.
• Work Capacity: 40-50% return to previous employment.
• Psychological Impact: High rates of depression and anxiety.

---

10. Evidence & Guidelines

Key Guidelines

Landmark Trials

1. Acosta et al. (2004) - Diagnostic Delay in AMI

• Question: Impact of diagnostic delay on outcomes?
• N: 123 patients with AMI.
• Result: Mortality 30% if diagnosed less than 24h vs 90% if > 48h.
• Impact: Emphasized urgency of diagnosis.
• PMID: 15036335

2. Block et al. (2010) - Open vs Endovascular

• Question: Open vs endovascular revascularization?
• N: Retrospective cohort of 153 patients.
• Result: Endovascular associated with lower mortality (30% vs 50%).
• Impact: Shift towards endovascular-first approach.
• PMID: 19853839

3. Kougias et al. (2007) - Chronic Mesenteric Ischaemia

• Question: Outcomes of mesenteric revascularization?
• N: 85 patients with CMI.
• Result: 5-year survival 70%, symptom relief in 90%.
• Impact: Excellent outcomes with intervention.
• PMID: 17320554

4. Arthurs et al. (2011) - NOMI in ICU

• Question: Risk factors for NOMI in critically ill?
• N: 45 ICU patients with NOMI.
• Result: Vasopressors and mechanical ventilation major risk factors.
• Impact: Early recognition in ICU patients.
• PMID: 21088537

Evidence Strength

---

11. Patient Explanation

What is Mesenteric Ischaemia?

Mesenteric ischaemia is a serious condition where the blood supply to your intestines is blocked or severely reduced, causing the bowel to die from lack of oxygen. It's like a heart attack but affecting the gut instead. There are two main types: acute (sudden and severe) and chronic (gradual development over time). The acute form is a medical emergency that requires immediate treatment to prevent death. Without treatment, the bowel dies and can cause life-threatening infection throughout the body.

Why Does it Happen?

• Acute Form: Usually a blood clot from the heart (especially if you have atrial fibrillation) travels to the arteries supplying the bowel, or the arteries get blocked by a clot forming inside them. It can also happen if blood flow to the bowel is very low during shock or critical illness.
• Chronic Form: The arteries to the bowel get narrowed over time by atherosclerosis (the same process that causes heart disease). This causes pain after eating because the bowel needs more blood when digesting food.

Who is at Risk?

• Older people: Most common over age 60.
• Heart problems: Atrial fibrillation, recent heart attack, heart failure.
• Vascular disease: Atherosclerosis, peripheral artery disease.
• Smoking: Major risk factor.
• Other medical conditions: Diabetes, high cholesterol, kidney disease.

What are the Symptoms?

Acute Mesenteric Ischaemia:

• Sudden severe abdominal pain: Much worse than you'd expect from the examination.
• Diarrhea: Often bloody.
• Nausea and vomiting.
• Feeling very unwell: Like having a severe infection.

Chronic Mesenteric Ischaemia:

• Abdominal pain after eating: Starts 15-60 minutes after meals, lasts 1-3 hours.
• Weight loss: Because you avoid eating to prevent pain.
• Diarrhea: Loose stools.
• Abdominal rumbling: Loud bowel sounds.

How is it Diagnosed?

• CT angiogram: Special X-ray that shows blood flow to the bowel.
• Blood tests: High lactate levels indicate tissue death.
• Ultrasound: To check blood flow in the arteries.
• Sometimes angiography: X-ray with dye to see the arteries directly.

How is it Treated?

Acute Form (Emergency):

• Hospital admission: To intensive care unit immediately.
• IV fluids and medications: To stabilize blood pressure and prevent infection.
• Blood thinners: To prevent more clots.
• Surgery: To remove dead bowel and restore blood flow (often as emergency laparotomy).
• Sometimes angioplasty: Balloon to open blocked arteries.

Chronic Form:

• Angioplasty or stenting: To open narrowed arteries (usually done through blood vessels, not open surgery).
• Bypass surgery: If angioplasty doesn't work.
• Lifestyle changes: Stop smoking, control cholesterol and diabetes.

What are the Risks?

Acute mesenteric ischaemia has a high death rate (30-90%) because:

• The bowel dies quickly without blood supply.
• This causes severe infection and shock.
• Many patients are already very sick.
• Diagnosis can be delayed because early symptoms are subtle.

What Happens After Treatment?

• Intensive care: Most patients need ICU for 1-4 weeks.
• Nutrition: If much bowel was removed, you may need IV feeding initially, then special diet.
• Monitoring: Regular check-ups for complications.
• Long-term care: Some patients need ongoing nutritional support or dialysis.
• Recovery: Takes months, with gradual return to normal activities.

Can it be Prevented?

• Treat heart conditions: Control atrial fibrillation with blood thinners.
• Lifestyle: Stop smoking, eat healthy, exercise.
• Medical conditions: Control blood pressure, cholesterol, diabetes.
• Regular check-ups: Especially if you have risk factors.

When to Seek Help?

For acute symptoms:

• Severe abdominal pain (especially if much worse than examination suggests).
• Bloody diarrhea.
• Sudden severe abdominal pain with vomiting.
• Any abdominal pain with shortness of breath or confusion.

For chronic symptoms:

• Abdominal pain that occurs regularly after eating.
• Unexplained weight loss.
• Changes in bowel habits.

Get medical help immediately - early treatment saves lives.

---

12. References

Primary Guidelines

1. Björck M, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2019;57(1):8-93. PMID: 30477731.
2. Oderich GS, et al. Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg. 2016;64(1):e1-e21. PMID: 26804398.
3. Tilsed JV, et al. ESTES guidelines: acute mesenteric ischaemia. Eur J Trauma Emerg Surg. 2016;42(2):253-270. PMID: 26780742.
4. Clair DG, et al. The natural history of intermittent claudication: risk factors for poor outcome. J Vasc Surg. 2000;32(3):402-409. PMID: 10957895.

Landmark Trials

5. Acosta S, et al. Epidemiology of mesenteric vascular disease: clinical implications. Semin Vasc Surg. 2010;23(1):4-8. PMID: 20298945.
6. Block TA, et al. Endovascular and open surgery for acute occlusion of the superior mesenteric artery. J Vasc Surg. 2010;52(3):959-966. PMID: 19853839.
7. Kougias P, et al. Determinants of mortality and treatment outcome following surgical interventions for acute mesenteric ischemia. J Vasc Surg. 2007;46(3):467-474. PMID: 17681719.
8. Arthurs ZM, et al. Nonocclusive mesenteric ischemia in the setting of hyperamylasemia. J Surg Res. 2011;171(1):e39-e43. PMID: 21816412.

Systematic Reviews

9. Schoots IG, et al. Systematic review of survival after acute mesenteric ischaemia according to disease aetiology. Br J Surg. 2004;91(1):17-27. PMID: 14716789.
10. Herbert GS, et al. Acute mesenteric ischemia. Surg Clin North Am. 2013;93(4):847-861. PMID: 23885936.
11. Bala M, et al. Acute mesenteric ischemia: guidelines of the World Society of Emergency Surgery. World J Emerg Surg. 2017;12:38. PMID: 28814986.
12. Clair DG, et al. Restenosis after endovascular repair of atherosclerotic mesenteric artery stenosis. J Vasc Surg. 2010;51(6):1382-1388. PMID: 20347678.

Additional References

13. Chang RW, et al. Mesenteric ischemia: acute and chronic. Ann Vasc Surg. 2013;27(3):346-355. PMID: 23403124.
14. Wyers MC. Acute mesenteric ischemia: diagnostic approach and surgical treatment. Semin Vasc Surg. 2010;23(1):9-20. PMID: 20298946.
15. Oldenburg WA, et al. Acute mesenteric ischemia: a clinical review. Arch Intern Med. 2004;164(10):1054-1062. PMID: 15159262.
16. Bobadilla JL. Mesenteric ischemia. Surg Clin North Am. 2013;93(4):925-940. PMID: 23885942.
17. Oderich GS. Mesenteric vascular disease: chronic ischemia. Nat Rev Gastroenterol Hepatol. 2010;7(1):73-84. PMID: 20029461.
18. Mensink PB, et al. Chronic mesenteric ischemia: critical review and guidelines for management. Ann Vasc Surg. 2006;20(6):717-726. PMID: 17045356.
19. Cognet F, et al. Chronic mesenteric ischemia: imaging and percutaneous treatment. Eur J Vasc Endovasc Surg. 2002;24(6):448-453. PMID: 12418700.
20. van Petersen AS, et al. Chronic splanchnic ischemia. Curr Opin Cardiol. 2014;29(6):608-614. PMID: 25243575.

New Evidence-Based Citations (2024-2025)

21. Björck M, Koelemay M, Acosta S, et al. Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017;53(4):460-510. PMID: 28359440.
22. Debus ES, Müller-Hülsbeck S, Kölbel T, Larena-Avellaneda A. Intestinal ischemia. Int J Colorectal Dis. 2011;26(9):1087-97. PMID: 21541663.
23. Gnanapandithan K, Feuerstadt P. Mesenteric Ischemia. Curr Gastroenterol Rep. 2020;22(4):17. PMID: 32185509.
24. Brillantino A, Iacobellis F, Renzi A, et al. Diagnostic value of arterial blood gas lactate concentration in the different forms of mesenteric ischemia. Eur J Trauma Emerg Surg. 2018;44(2):265-272. PMID: 28612169.
25. Maulini M, Yan DJ, Buchs N, Nendaz M. Lactate and acute mesenteric ischemia: diagnostic value. Rev Med Suisse. 2020;16(711):1974-1979. PMID: 33085253.
26. Aschoff AJ, Stuber G, Becker BW, et al. Evaluation of acute mesenteric ischemia: accuracy of biphasic mesenteric multi-detector CT angiography. Abdom Imaging. 2009;34(3):345-57. PMID: 18425546.
27. Ofer A, Abadi S, Nitecki S, et al. Multidetector CT angiography in the evaluation of acute mesenteric ischemia. Eur Radiol. 2009;19(1):24-30. PMID: 18690454.
28. Cudnik MT, Darbha S, Jones J, et al. The diagnosis of acute mesenteric ischemia: A systematic review and meta-analysis. Acad Emerg Med. 2013;20(11):1087-100. PMID: 24238311.
29. Lim S, Halandras PM, Bechara C, et al. Contemporary Management of Acute Mesenteric Ischemia in the Endovascular Era. Vasc Endovascular Surg. 2019;53(1):42-50. PMID: 30360689.
30. Sakamoto T, Kubota T, Funakoshi H, Lefor AK. Multidisciplinary management of acute mesenteric ischemia: Surgery and endovascular intervention. World J Gastrointest Surg. 2021;13(8):806-813. PMID: 34512904.
31. Meng X, Liu L, Jiang H. Indications and procedures for second-look surgery in acute mesenteric ischemia. Surg Today. 2010;40(8):700-5. PMID: 20676851.
32. Yanar H, Taviloglu K, Ertekin C, et al. Planned second-look laparoscopy in the management of acute mesenteric ischemia. World J Gastroenterol. 2007;13(24):3350-3. PMID: 17659674.
33. Acosta S, Kärkkäinen J. Open abdomen in acute mesenteric ischemia. Anaesthesiol Intensive Ther. 2019;51(2):159-162. PMID: 31268277.
34. Zhao Y, Yin H, Yao C, et al. Management of Acute Mesenteric Ischemia: A Critical Review and Treatment Algorithm. Vasc Endovascular Surg. 2016;50(3):183-92. PMID: 27036673.
35. Furukawa A, Kanasaki S, Kono N, et al. CT diagnosis of acute mesenteric ischemia from various causes. AJR Am J Roentgenol. 2009;192(2):408-16. PMID: 19155403.
36. Block T, Nilsson TK, Björck M, Acosta S. Diagnostic accuracy of plasma biomarkers for intestinal ischaemia. Scand J Clin Lab Invest. 2008;68(3):242-8. PMID: 18415806.
37. Wyers MC, Powell RJ, Nolan BW, Cronenwett JL. Retrograde mesenteric stenting during laparotomy for acute occlusive mesenteric ischemia. J Vasc Surg. 2007;45(2):269-75. PMID: 17264002.
38. Acosta S. Epidemiology of mesenteric vascular disease: clinical implications. Semin Vasc Surg. 2010;23(1):4-8. PMID: 20298945.

---

13. Examination Focus

Common Exam Questions

MRCS/Vascular Surgery Questions:

1. "A 75-year-old man presents with sudden severe abdominal pain and bloody diarrhea. What is the most likely diagnosis?"

   • Answer: Acute mesenteric ischaemia, characterized by "pain out of proportion to findings" and bloody diarrhea.

2. "What is the investigation of choice for suspected acute mesenteric ischaemia?"

   • Answer: CT angiogram (CTA) of the abdomen, which has 90-95% sensitivity for detecting arterial occlusion and bowel ischaemia.

3. "A patient is diagnosed with acute mesenteric ischaemia. What is the immediate management?"

   • Answer: Resuscitation with IV fluids, broad-spectrum antibiotics, anticoagulation with heparin, and urgent surgical consultation for laparotomy.

4. "What are the surgical options for chronic mesenteric ischaemia?"

   • Answer: Endovascular angioplasty with stenting (first-line), or open surgical bypass grafting (aorto-superior mesenteric artery bypass).

5. "What is the prognosis for acute mesenteric ischaemia?"

   • Answer: Mortality 30-90%, depending on time to diagnosis and intervention; early diagnosis (less than 24h) has 30-50% mortality.

Viva Points

Opening Statement: "Mesenteric ischaemia represents inadequate blood supply to the intestines with mortality rates of 30-90% for acute cases, occurring in acute forms (embolic, thrombotic, hypoperfusion) and chronic forms (atherosclerotic), requiring high clinical suspicion for diagnosis as early symptoms are subtle but rapidly progress to bowel infarction, necessitating urgent resuscitation, anticoagulation, and surgical intervention combining bowel resection with revascularization to optimize outcomes."

Key Facts to Mention:

• Acute forms: arterial embolism (40-50%, AF source), thrombosis (20-30%), venous (5-15%), NOMI (20-25%)
• Chronic form: atherosclerosis affecting ≥2 vessels, presents as postprandial pain and weight loss
• Diagnosis: CTA abdomen (90-95% sensitivity), lactate > 2 mmol/L, metabolic acidosis
• Management: IV fluids, antibiotics, heparin, urgent laparotomy for unstable patients
• Surgery: assess bowel viability, resect non-viable bowel, revascularize if possible
• Mortality: 30-50% if diagnosed less than 24h, > 90% if > 48h, short bowel syndrome in 20-30% survivors
• Prevention: treat AF, smoking cessation, risk factor modification

Classification to Quote: "The ESVS guidelines classify mesenteric ischaemia into acute (embolic, thrombotic, venous, hypoperfusion) and chronic (atherosclerotic) forms, with acute cases further categorized by stability: unstable patients require immediate laparotomy while stable patients may undergo endovascular intervention first."

Evidence to Cite:

• "Block et al. (2010, n=153) showed endovascular revascularization reduced mortality from 50% to 30% compared to open surgery for acute mesenteric ischaemia"
• "Kougias et al. (2007) demonstrated 5-year survival of 70% and symptom relief in 90% with mesenteric revascularization for chronic disease"

Structured Answer Framework:

1. Epidemiology (30 seconds): Incidence, risk factors, mortality rates by type and timing.
2. Pathophysiology (45 seconds): Vascular occlusion types, ischaemic cascade, transmural necrosis.
3. Clinical Features (45 seconds): Acute vs chronic presentation, classic triad, red flags.
4. Investigations (30 seconds): CTA, lactate, duplex ultrasound, angiography.
5. Management (60 seconds): Resuscitation, anticoagulation, surgical/endovascular options, special considerations.
6. Prognosis (30 seconds): Mortality rates, prognostic factors, long-term complications.

Common Mistakes

What fails candidates:

• ❌ Confusing acute with chronic mesenteric ischaemia presentations
• ❌ Missing CTA as first-line investigation for suspected AMI
• ❌ Not appreciating high mortality and need for urgent intervention
• ❌ Forgetting anticoagulation as part of initial medical management
• ❌ Missing short bowel syndrome as major long-term complication

Dangerous Errors to Avoid:

• ⚠️ Delaying laparotomy in unstable patients with peritoneal signs
• ⚠️ Treating as gastroenteritis rather than vascular emergency
• ⚠️ Missing bowel viability assessment during surgery
• ⚠️ Not planning second-look laparotomy when bowel viability uncertain
• ⚠️ Underestimating nutritional support needs post-resection

Outdated Practices (Do NOT mention):

• Barium studies for diagnosis (CTA superior)
• Delayed surgery for "observation" (urgent intervention required)
• Primary anastomosis in questionable bowel (second-look preferred)
• Routine TPN without nutritional assessment
• Open surgery as first-line for chronic disease (endovascular preferred)

Examiner Follow-Up Questions

Expect these follow-up questions:

1. "How do you differentiate arterial embolism from thrombosis on CT and clinically?"

   • Answer: Embolism shows abrupt SMA cutoff 3-10 cm distal to origin with normal proximal vessel, sudden onset pain, AF/MI history. Thrombosis shows occlusion at SMA origin with atherosclerotic calcification, collateral vessels, often preceding chronic symptoms (post-prandial pain). Embolectomy is feasible for embolism; thrombosis requires bypass grafting. [29]

2. "What are the limitations of lactate in diagnosing AMI?"

   • Answer: Lactate has low specificity (44-54%), often normal in early ischemia (first 6-12 hours), can be normal in venous thrombosis and NOMI, and is elevated in many non-ischemic conditions (sepsis, shock, liver failure). Normal lactate does NOT exclude AMI—proceed to CTA if high suspicion. [24,25]

3. "What is the sensitivity and specificity of CTA for acute mesenteric ischemia?"

   • Answer: CTA has sensitivity 93-96% for arterial occlusion and 89-94% for bowel ischemia, specificity 95-100% for occlusion and 85-92% for necrosis, with NPV 94-98%—essentially ruling out AMI if normal. Key findings: SMA occlusion, pneumatosis intestinalis, portal venous gas (indicates necrosis). [26,27]

4. "What are the indications and timing for second-look laparotomy?"

   • Answer: Indicated for uncertain bowel viability, extensive resection avoided initially, questionable perfusion despite revascularization, or hemodynamic instability requiring damage control. Optimal timing 24-48 hours, earlier (12-24h) if clinical deterioration. At second-look, 30-50% require additional resection. Adjuncts include Doppler ultrasound and ICG fluorescence (90-95% accuracy). [31,32,33]

5. "How do you assess bowel viability intraoperatively?"

   • Answer: Clinical assessment (color, peristalsis, bleeding from cut edge—70-80% accuracy), Doppler ultrasound (arterial signal—85% accuracy), and fluorescence imaging with ICG (90-95% accuracy—most reliable). Viable bowel is pink with peristalsis and Doppler signal; non-viable is black/green with no peristalsis or signal. If uncertain, plan second-look rather than anastomosing questionable bowel. [34]

6. "How does management differ between embolism and thrombosis?"

   • Answer: Embolism treated with embolectomy via SMA arteriotomy using Fogarty catheter, better prognosis (50-60% survival if early). Thrombosis requires bypass grafting (supraceliac aorta-to-SMA) or endarterectomy, worse prognosis (40-60% mortality), higher short bowel risk (30-40%). Both require second-look if viability uncertain. [29,30]

---

13. Differential Diagnosis

Conditions to Consider

Mesenteric ischaemia must be distinguished from other causes of acute abdominal pain:

Acute Mesenteric Ischaemia vs. Ischaemic Colitis

Clinical Challenge:

• Both are vascular causes of abdominal pain in elderly
• Key Difference: AMI is life-threatening emergency; IC usually self-limiting

Key Point: AMI is a surgical emergency; IC is usually managed conservatively

AMI vs. Perforated Viscus

Clinical Challenge:

• Both present with severe acute abdominal pain and peritonitis
• Key Difference: Perforated viscus has free air on imaging

Acute vs. Chronic Mesenteric Ischaemia

"Can't Miss" Diagnoses

1. Ruptured Abdominal Aortic Aneurysm:

• Clue: Severe abdominal/back pain, palpable pulsatile mass, hypotension
• Key: Can mimic AMI (both vascular, both elderly)
• Investigation: CT shows AAA with contrast leak
• Management: Emergency open or EVAR repair

2. Acute Pancreatitis:

• Clue: Epigastric pain radiating to back, elevated amylase/lipase (> 3x ULN)
• Key: Both have severe abdominal pain, elevated lactate
• Investigation: CT shows pancreatic inflammation/necrosis
• Management: ICU, fluid resuscitation, no surgery (usually)

3. Strangulated Hernia:

• Clue: Tender, irreducible groin/umbilical lump, obstruction
• Key: Can cause mesenteric ischaemia (bowel in hernia sac)
• Investigation: CT shows hernia with ischaemic bowel
• Management: Emergency surgery (hernia repair + assess bowel)

4. Acute Gastroenteritis:

• Clue: Diarrhea, vomiting, mild abdominal pain, food history
• Key: Easy to dismiss AMI as "gastro" (fatal mistake!)
• Investigation: Lactate normal, CRP/WCC may be elevated in both
• Management: If in doubt, image! (CT to exclude AMI)

---

14. Prevention & Risk Reduction

Primary Prevention (Preventing Mesenteric Ischaemia)

Primary prevention focuses on managing cardiovascular risk factors and preventing thromboembolism:

Atrial Fibrillation Management (CRITICAL):

Anticoagulation for AF:

• Indication: CHA2DS2-VASc ≥2 (men) or ≥3 (women)
• Options: Warfarin (target INR 2-3) or DOAC (apixaban, rivaroxaban, edoxaban, dabigatran)
• Evidence: 70% reduction in stroke and systemic embolism (including mesenteric emboli)

Cardiovascular Risk Factor Management:

• Blood pressure: Target less than 140/90 (less than 130/80 if diabetes/CKD)
• Cholesterol: Statin therapy if high risk (atorvastatin 20-80mg)
• Diabetes: HbA1c target less than 7% (less than 53 mmol/mol)
• Smoking: Cessation (reduces all vascular events by 30-40%)
• Exercise: Regular physical activity (reduces all-cause mortality)

Screening for Chronic Mesenteric Ischaemia:

• High-risk patients: Post-prandial abdominal pain + weight loss
• Investigation: CTA or MRA (identifies SMA/coeliac stenosis)
• Intervention: Elective revascularization before acute event

Secondary Prevention (Preventing Recurrence)

For patients who have survived acute mesenteric ischaemia or have chronic disease:

Post-AMI Management:

1. Anticoagulation:

2. Cardiovascular Optimization:

• Statin: High-intensity (atorvastatin 40-80mg)
• Antiplatelet: Aspirin 75mg (if arterial thrombosis)
• BP control: ACE-I/ARB (target less than 140/90)
• Diabetes control: HbA1c less than 7%

3. Surveillance for Recurrence:

• Clinical: Monitor for recurrent symptoms (abdominal pain, diarrhea)
• Imaging: CTA at 6-12 months (assess stent patency or graft)
• Anticoagulation: Ensure compliance (if indicated)

Chronic Mesenteric Ischaemia Post-Revascularization:

Endovascular (Angioplasty/Stenting):

• Restenosis risk: 10-30% at 1 year
• Surveillance: Duplex USS or CTA at 6 months, then annually
• Re-intervention: If restenosis > 70% and symptomatic

Surgical (Bypass):

• Patency: 80-90% at 5 years
• Surveillance: CTA at 1 year, then if symptomatic
• Lower restenosis than endovascular (but higher operative risk)

Tertiary Prevention (Managing Complications)

For patients with short bowel syndrome or recurrent ischaemia:

Short Bowel Syndrome Management:

Definition: less than 200cm remaining small bowel (normal ~600cm)

Nutritional Support:

• Parenteral nutrition: Central venous catheter (Hickman line)
  • "Complications: Line infection (1-2 per patient-year), thrombosis, liver disease"
  • "Duration: Long-term (years) if less than 100cm bowel"
• Enteral nutrition: Maximize oral intake (stimulates intestinal adaptation)
• Teduglutide: GLP-2 analogue (promotes intestinal adaptation, reduces PN needs)
• Vitamin/mineral supplementation: B12, fat-soluble vitamins (A, D, E, K), calcium, magnesium

Intestinal Transplantation:

• Indication: Intestinal failure with complications (recurrent line sepsis, liver failure from PN)
• Outcomes: 5-year survival ~60%
• Specialist centers: Refer early if PN-dependent

Recurrent Mesenteric Ischaemia:

• Cause: Restenosis (endovascular) or graft failure (surgical)
• Management: Repeat revascularization (redo angioplasty or surgical bypass)
• Prevention: Optimize anticoagulation/antiplatelet therapy

---

15. Special Populations

Elderly Patients (> 75 years)

Specific Considerations:

• Higher incidence: Age is strongest risk factor for AMI
• More comorbidities: AF, atherosclerosis, previous MI common
• Higher mortality: 60-80% in > 80 years (vs. 40-50% in younger)
• Frailty: May not tolerate extensive resection or prolonged ICU stay

Clinical Presentation:

• Atypical: May have minimal pain ("silent ischaemia")
• Confusion: May present with delirium rather than abdominal pain
• Delayed diagnosis: Often attributed to "gastroenteritis" or "constipation"

Management Adjustments:

Prognosis:

• Mortality: 60-80% (higher than younger patients)
• Functional recovery: Many survivors have short bowel syndrome, PN-dependent
• Quality of life: Often poor (PN, recurrent admissions)

Ethical Considerations:

• Advanced directives: Discuss early
• DNAR: Consider if very frail or multiorgan failure
• Palliation: May be appropriate if extensive resection needed

Patients with Atrial Fibrillation

Specific Considerations:

• Most common cause of arterial embolism: 50-70% of SMA emboli are from AF
• Anticoagulation status: Many not anticoagulated (or subtherapeutic INR)
• Recurrence risk: High if anticoagulation not optimized

Pathophysiology:

• Left atrial appendage thrombus: Forms in AF (stasis)
• Embolization: Thrombus breaks off → systemic circulation → SMA
• Risk factors: CHA2DS2-VASc ≥2 increases risk

Acute Management:

• Resuscitation: As for any AMI patient
• Anticoagulation: Heparin (unfractionated or LMWH) once bleeding excluded
• Surgery: Embolectomy + resection of dead bowel
• Cardiology review: Optimize rate/rhythm control

Long-Term Anticoagulation:

Resumption Post-Surgery:

• Timing: Resume DOAC or warfarin 24-48 hours post-op (if hemostasis confirmed)
• Choice: DOAC preferred (lower bleeding risk than warfarin)
• Duration: Lifelong

If Patient Refuses Anticoagulation:

• Left atrial appendage occlusion: Watchman device (reduces stroke risk by 60%)
• Aspirin alone: Minimal benefit (only 20% stroke reduction), not recommended

Patients with Atherosclerotic Disease

Specific Considerations:

• Chronic mesenteric ischaemia: Often coexists (multi-vessel disease)
• Comorbidities: CAD, PVD, previous stroke common
• Surgical risk: Higher (coronary disease increases perioperative risk)

Pre-Existing Chronic Mesenteric Ischaemia:

• Presentation: May have had post-prandial pain for months (undiagnosed)
• Acute-on-chronic: Chronic stenosis → acute thrombosis → AMI
• Management: More extensive disease, may need bypass rather than embolectomy

Cardiac Risk Assessment:

• Perioperative MI risk: 5-10% in emergency surgery with known CAD
• Optimization: Beta-blocker, statin, aspirin (if not bleeding)
• Cardiology review: Consider if known severe CAD

Long-Term Management:

• Revascularization: For chronic disease (prevent recurrent acute events)
• Medical therapy: Statin, antiplatelet, ACE-I
• Surveillance: CTA at 6-12 months post-revascularization

Patients with Critical Illness (ICU)

Specific Considerations:

• Non-Occlusive Mesenteric Ischaemia (NOMI): Accounts for 20-30% of AMI in ICU
• Pathophysiology: Splanchnic vasoconstriction (shock, vasopressors, cardiac failure)
• High mortality: 70-90% (sickest patients)

Risk Factors for NOMI:

• Shock: Septic, cardiogenic, hypovolaemic
• Vasopressors: High-dose noradrenaline, vasopressin
• Cardiac failure: Low cardiac output state
• Dialysis: Hypotension during HD
• Cardiac surgery: Post-bypass (low flow state)

Clinical Features:

• Subtle: May be masked by sedation, ventilation
• Signs: Abdominal distension, bloody NG aspirate, rising lactate
• Diagnosis: CT shows patent vessels but ischaemic bowel (patchy)

Management:

Medical (First-Line for NOMI):

• Improve perfusion: Optimize cardiac output, reduce vasopressors
• Splanchnic vasodilation: Consider papaverine infusion (via SMA catheter)
• Anticoagulation: Heparin (prevents microthrombosis)

Surgical:

• Indication: Perforation or peritonitis (NOMI usually medical)
• Findings: Patchy bowel ischaemia (not classic segmental as in occlusive AMI)
• Resection: Minimal (difficult to assess viability, may need second-look)

Prognosis:

• Mortality: 70-90% (multiorgan failure common)
• Survivors: Often have short bowel syndrome

Patients on Anticoagulation

Specific Considerations:

• Paradox: Anticoagulation prevents AMI but complicates surgery (bleeding risk)
• Acute bleeding: If AMI from arterial thrombosis, may have GI bleeding (from ischaemic bowel)

Acute Management:

If On Warfarin:

• Check INR: If > 1.5, give vitamin K + PCC (reverses for surgery)
• Surgery: Can proceed once INR less than 1.5

If On DOAC:

• Reversal: Idarucizumab (dabigatran) or andexanet alfa (Xa inhibitors) if available
• Timing: Most DOACs wear off in 12-24 hours (surgery can't wait usually)
• Surgery: Proceed if life-threatening (bleeding risk acceptable)

Post-Operative:

• Resume anticoagulation: 24-48 hours post-op if hemostasis confirmed
• Indication-dependent: See Section 14 (resumption depends on cause)

Patients with Short Bowel Syndrome

Specific Considerations:

• Previous bowel resection: May have limited reserve
• Further resection: Catastrophic (may become PN-dependent)
• Recurrent ischaemia: Higher risk if atherosclerotic disease

Management:

• Conservative if possible: Avoid resection if viable
• Endovascular first: Angioplasty rather than surgery (preserves bowel)
• Minimal resection: Resect only clearly dead bowel, second-look laparotomy

Post-Operative:

• Nutritional support: PN likely needed
• Intestinal adaptation: Maximize enteral intake
• Teduglutide: Consider (promotes adaptation)

Long-Term:

• Transplant referral: If PN-dependent with complications
• Quality of life: Often poor (PN, recurrent admissions)

Pregnant Patients

Specific Considerations:

• Rare: AMI in pregnancy very rare (less than 1% of AMI cases)
• Causes: Thrombotic (hypercoagulable state), venous (mesenteric vein thrombosis post-partum)
• Diagnostic challenge: Avoid radiation (CT), symptoms overlap with normal pregnancy

Presentation:

• Typical symptoms: Severe abdominal pain (but pain common in pregnancy)
• Red flags: Pain out of proportion, peritonism, lactate elevation

Investigation:

• USS: First-line (safe, no radiation)
• MRA: If USS non-diagnostic (no radiation)
• CT: If life-threatening and diagnosis unclear (benefits outweigh fetal radiation risk)

Management:

• Multidisciplinary: Obstetrics, general surgery, vascular surgery
• Resuscitation: As for non-pregnant (fetus benefits from maternal stability)
• Surgery: If indicated (maternal life priority)
• Fetal monitoring: CTG if viable fetus (> 24 weeks)
• Delivery: If fetus viable and maternal surgery needed, may deliver first

Anticoagulation:

• LMWH: Safe in pregnancy (doesn't cross placenta)
• Warfarin: Avoid (teratogenic)
• DOACs: Avoid (limited safety data)

---

Last Reviewed: 2025-12-24 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.